{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:16:30Z","timestamp":1792167390546,"version":"4.4.0"},"reference-count":158,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011903","name":"Gedeon Richter Talentum Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011903","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Introduction: Optimal systemic treatment for recurrent or advanced endometrial cancer (EC) remains uncertain, particularly in the second-line setting. While first-line chemotherapy with paclitaxel and carboplatin is widely used, its efficacy is limited. Recent evidence suggests that adding immune checkpoint inhibitors (ICIs) to chemotherapy (ChT) can improve progression-free survival (PFS). In addition, hormonal therapies (such as progestins and aromatase inhibitors), targeted therapies and ICIs used alone or in combination are emerging as potential treatment options. Objectives: Our objective was to systematically evaluate the efficacy and safety of systemic therapies beyond standard ChT for patients with recurrent or advanced EC, focusing on progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs). Methods: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs), prospective studies, and retrospective studies up to June 2024 on PubMed, Embase, and CENTRAL. Studies evaluating systemic therapies\u2014chemotherapy, hormonal therapy, targeted agents, and ICIs\u2014in recurrent or advanced EC were included. Primary outcomes were PFS and OS; secondary outcomes included grade \u2265 3 treatment-related adverse events. Risk of bias was assessed using the Cochrane RoB 2 and MINORS tools, and GRADE was applied to evaluate the certainty of evidence. Results: Five RCTs evaluated the addition of ICI to conventional ChT. In mismatch repair-deficient (MMRd) patients, the addition of ICI significantly improved PFS and OS compared to the ChT-only group. In mismatch repair-deficient (MMRd) patients, the median PFS (mPFS) was 8.39 months in the ChT group and 22.73 months in the ICI group (HR: 0.34, p &lt; 0.001). OS results were 26.48 and 41.36 months, respectively. In mismatch repair-proficient (MMRp) patients, mPFS was 9.4 months in the ChT group and 10.18 months at the ICI group (HR: 0.72, p = 0.002). OS was 27.37 and 27.79 months, respectively. We conducted several exploratory single-arm subgroup analyses and multiple individual patient data (IPD) meta-analyses across several clinically relevant subgroups, including patients treated with progestins, lenvatinib plus pembrolizumab, PI3K\/AKT\/mTOR inhibitor monotherapy, and PI3K\/AKT\/mTOR inhibitors in combination with aromatase inhibitors. Detailed descriptive analyses were performed for each subgroup. Conclusions: Combining chemotherapy with ICIs appears to show the most favorable survival outcomes, especially in MMRd tumors. Taking into account the methodological limitations inherent in the elaboration of lower-level evidence and IPD, hormonal and targeted therapies might be considered viable options, with efficacy and safety profiles dependent on tumor biology. Better stratification of the EC patient cohort is warranted.<\/jats:p>","DOI":"10.3390\/cancers18132091","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T02:16:44Z","timestamp":1782699404000},"page":"2091","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic Treatment Strategies Beyond Chemotherapy in Recurrent or Advanced Endometrial Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"18","author":[{"given":"Istv\u00e1n","family":"Mad\u00e1r","sequence":"first","affiliation":[{"name":"Centre for Translational Medicine, Semmelweis University, 1088 Budapest, Hungary"},{"name":"Department of Obstetrics and Gynecology, Semmelweis University, 1088 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anett","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"Centre for Translational Medicine, Semmelweis University, 1088 Budapest, Hungary"},{"name":"Department of Urology, Semmelweis University, 1082 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2804-6524","authenticated-orcid":false,"given":"Bianca Golzio Navarro","family":"Cavalcante","sequence":"additional","affiliation":[{"name":"Centre for Translational Medicine, Semmelweis University, 1088 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Vlesk\u00f3","sequence":"additional","affiliation":[{"name":"Centre for Translational Medicine, Semmelweis University, 1088 Budapest, Hungary"},{"name":"Department of Obstetrics and Gynecology, Semmelweis University, 1088 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Hegyi","sequence":"additional","affiliation":[{"name":"Centre for Translational Medicine, Semmelweis University, 1088 Budapest, Hungary"},{"name":"Institute for Translational Medicine, Medical School, University of P\u00e9cs, 7624 P\u00e9cs, Hungary"},{"name":"Institute of Pancreatic Diseases, Semmelweis University, 1083 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00e1ndor","family":"\u00c1cs","sequence":"additional","affiliation":[{"name":"Centre for Translational Medicine, Semmelweis University, 1088 Budapest, Hungary"},{"name":"Department of Obstetrics and Gynecology, Semmelweis University, 1088 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"K\u00f3i","sequence":"additional","affiliation":[{"name":"Centre for Translational Medicine, Semmelweis University, 1088 Budapest, Hungary"},{"name":"Stochastics Department, Budapest University of Technology and Economics, 1111 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"K\u00e1lovics","sequence":"additional","affiliation":[{"name":"Centre for Translational Medicine, Semmelweis University, 1088 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"Centre for Translational Medicine, Semmelweis University, 1088 Budapest, Hungary"},{"name":"Department of Obstetrics and Gynecology, Semmelweis University, 1088 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"ref_1","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"key":"ref_3","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","article-title":"Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma","volume":"355","author":"Creutzberg","year":"2000","journal-title":"Lancet"},{"key":"ref_5","first-page":"179","article-title":"Factors predicting recurrent endometrial cancer","volume":"5","author":"Huijgens","year":"2013","journal-title":"Facts Views Vis. ObGyn"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Mad\u00e1r, I., Szab\u00f3, A., Vlesk\u00f3, G., Hegyi, P., \u00c1cs, N., Feh\u00e9rv\u00e1ri, P., K\u00f3i, T., K\u00e1lovics, E., and Szab\u00f3, G. (2024). Diagnostic Accuracy of Transvaginal Ultrasound and Magnetic Resonance Imaging for the Detection of Myometrial Infiltration in Endometrial Cancer: A Systematic Review and Meta-Analysis. Cancers, 16.","DOI":"10.3390\/cancers16050907"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The Cancer Genome Atlas Pan-Cancer analysis project","volume":"45","author":"Weinstein","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kalampokas, E., Giannis, G., Kalampokas, T., Papathanasiou, A.A., Mitsopoulou, D., Tsironi, E., Triantafyllidou, O., Gurumurthy, M., Parkin, D.E., and Cairns, M. (2022). Current Approaches to the Management of Patients with Endometrial Cancer. Cancers, 14.","DOI":"10.3390\/cancers14184500"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1634\/theoncologist.2010-0087","article-title":"Endometrial carcinoma: A review of chemotherapy, drug resistance, and the search for new agents","volume":"15","author":"Moxley","year":"2010","journal-title":"Oncologist"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ygyno.2019.12.039","article-title":"Second-line lenvatinib in patients with recurrent endometrial cancer","volume":"156","author":"Vergote","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Bostan, I.S., Mihaila, M., Roman, V., Radu, N., Neagu, M.T., Bostan, M., and Mehedintu, C. (2024). Landscape of Endometrial Cancer: Molecular Mechanisms, Biomarkers, and Target Therapy. Cancers, 16.","DOI":"10.3390\/cancers16112027"},{"key":"ref_17","first-page":"143","article-title":"The effect of progestin therapy in advanced and recurrent endometrial cancer: A systematic review and meta-analysis","volume":"130","author":"Birkendahl","year":"2023","journal-title":"BJOP"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ygyno.2017.07.002","article-title":"Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis","volume":"147","author":"Ethier","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-12-0662","article-title":"The PI3K\/AKT\/mTOR pathway as a therapeutic target in endometrial cancer","volume":"18","author":"Slomovitz","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1038\/s41591-024-03315-w","article-title":"Systems education can train the next generation of scientists and clinicians","volume":"30","author":"Hegyi","year":"2024","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Hegyi, P., Petersen, O.H., Holgate, S., Er\u0151ss, B., Garami, A., Szak\u00e1cs, Z., Dobszai, D., Balask\u00f3, M., Kem\u00e9ny, L., and Peng, S. (2020). Academia Europaea Position Paper on Translational Medicine: The Cycle Model for Translating Scientific Results into Community Benefits. J. Clin. Med., 9.","DOI":"10.3390\/jcm9051532"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1038\/s41591-025-03992-1","article-title":"Academia Europaea\u2019s guidelines for the visualization of clinical outcomes","volume":"31","author":"Hegyi","year":"2025","journal-title":"Nat. Med."},{"key":"ref_25","unstructured":"(2023). GRADEpro GDT: GRADEpro Guideline Development Tool [Software], Evidence Prime."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Harrer, M., Cuijpers, P., Furukawa, T.A., and Ebert, D.D. (2021). Doing Meta-Analysis with R: A Hands-On Guide, Chapman & Hall\/CRC Press. [1st ed.].","DOI":"10.1201\/9781003107347"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1164","article-title":"Methods to estimate the between-study variance and its uncertainty in meta-analysis","volume":"7","author":"Veroniki","year":"2016","journal-title":"Res. Synth. Methods"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"IntHout, J., Ioannidis, J.P., and Borm, G.F. (2014). The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med. Res. Methodol., 14.","DOI":"10.1186\/1471-2288-14-25"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Schwarzer, G., Carpenter, J.R., R\u00fccker, G., Schwarzer, G., Carpenter, J.R., and R\u00fccker, G. (2015). Meta-Analysis with Binary Outcomes, Springer.","DOI":"10.1007\/978-3-319-21416-0"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Liu, N., Zhou, Y., and Lee, J.J. (2021). IPDfromKM: Reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol., 21.","DOI":"10.1186\/s12874-021-01308-8"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1002\/sim.6111","article-title":"Meta-analysis of single-arm survival studies: A distribution-free approach for estimating summary survival curves with random effects","volume":"33","author":"Combescure","year":"2014","journal-title":"Stat. Med."},{"key":"ref_34","unstructured":"Cuijpers, P., Furukawa, T., Ebert, D.D., and Harrer, M. (2023, December 23). Dmetar: Companion R Package for the Guide Doing Meta-Analysis in R. Available online: https:\/\/dmetar.protectlab.org."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ygyno.2019.10.013","article-title":"Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2\u2014A randomized phase II trial","volume":"155","author":"Lorusso","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ygyno.2014.12.004","article-title":"A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA)","volume":"136","author":"Simpkins","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygyno.2018.05.018","article-title":"A phase II study of frontline paclitaxel\/carboplatin\/bevacizumab, paclitaxel\/carboplatin\/temsirolimus, or ixabepilone\/carboplatin\/bevacizumab in advanced\/recurrent endometrial cancer","volume":"150","author":"Aghajanian","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e934493","DOI":"10.12659\/MSM.934493","article-title":"Efficacy of PD-1 Inhibitor Combined with Bevacizumab in Treatment of Advanced Endometrial Cancer Patients with Mismatch Repair Deficiency (dMMR)\/High-Level Microsatellite Instability (MSI-H)","volume":"28","author":"Liao","year":"2022","journal-title":"Med. Sci. Monit."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/IGC.0000000000000891","article-title":"Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma","volume":"27","author":"Rose","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"101026","DOI":"10.1016\/j.gore.2022.101026","article-title":"Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatch repair proficient (pMMR) in the United States","volume":"42","author":"Kelkar","year":"2022","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ygyno.2022.10.016","article-title":"Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States","volume":"169","author":"Kelkar","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_42","first-page":"3525","article-title":"Bevacizumab therapy in patients with recurrent uterine neoplasms","volume":"27","author":"Wright","year":"2007","journal-title":"Anticancer. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2\/Neu (NCT01367002): Updated Overall Survival Analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2010.32.6397","article-title":"Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2012.12.022","article-title":"Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study","volume":"129","author":"Alvarez","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ygyno.2021.04.016","article-title":"Bevacizumab in advanced endometrial cancer","volume":"161","author":"Rubinstein","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ygyno.2015.03.008","article-title":"Weekly ixabepilone with or Without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian\/primary peritoneal\/fallopian tube cancers: A retrospective review","volume":"137","author":"Roque","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in Patients with Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study","volume":"40","author":"Bariani","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1200\/JCO.19.01021","article-title":"Phase II Study of Avelumab in Patients with Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent\/Persistent Endometrial Cancer","volume":"37","author":"Konstantinopoulos","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ygyno.2022.11.029","article-title":"Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)\/ microsatellite instability high (MSI-high) endometrial carcinoma","volume":"169","author":"Colomba","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/cncr.34025","article-title":"A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability","volume":"128","author":"Bellone","year":"2022","journal-title":"Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e002255","DOI":"10.1136\/jitc-2020-002255","article-title":"Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial","volume":"9","author":"Antill","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e2341165","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients with Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial","volume":"6","author":"Berton","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ygyno.2022.11.028","article-title":"Durvalumab with or Without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study","volume":"169","author":"Rubinstein","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ygyno.2022.02.025","article-title":"Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)","volume":"165","author":"Post","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jamaoncol.2022.2181","article-title":"Evaluation of Treatment with Talazoparib and Avelumab in Patients with Recurrent Mismatch Repair Proficient Endometrial Cancer","volume":"8","author":"Konstantinopoulos","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e004338","DOI":"10.1136\/jitc-2021-004338","article-title":"Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer","volume":"10","author":"Wei","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e004233","DOI":"10.1136\/jitc-2021-004233","article-title":"Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer","volume":"10","author":"Lheureux","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/ijgc-2022-003345","article-title":"Anlotinib in recurrent or metastatic endometrial cancer","volume":"32","author":"Cui","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"How, J.A., Jazaeri, A.A., Fu, S., Rodon Ahnert, J., Gong, J., Stephen, B., Ferreira Dalla Pria, H., Bhosale, P., Johnson, A., and Yuan, Y. (2022). Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials. Cancers, 14.","DOI":"10.3390\/cancers14153695"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00262-022-03253-x","article-title":"Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study","volume":"72","author":"Tuyaerts","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s41467-023-37084-w","article-title":"Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or Without dostarlimab in recurrent endometrial carcinoma","volume":"14","author":"Madariaga","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II Trial of Lenvatinib Plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ygyno.2022.02.020","article-title":"Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea","volume":"165","author":"Kim","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2021.04.034","article-title":"Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer","volume":"162","author":"How","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/jjco\/hyad192","article-title":"A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: Insights from ProMisE molecular classification system","volume":"54","author":"Chiba","year":"2024","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.22.01021","article-title":"A Phase Ib\/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111\/KEYNOTE-146): Long-Term Efficacy and Safety Update","volume":"41","author":"Makker","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1136\/ijgc-2024-005331","article-title":"Low-dose lenvatinib and anti-programmed cell death protein-1 combination therapy in patients with heavily pre-treated recurrent ovarian and endometrial cancer: A pilot study","volume":"34","author":"Shang","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1620\/tjem.2023.J095","article-title":"Lenvatinib plus Pembrolizumab Combination Therapy for Advanced or Recurrent Endometrial Cancer: A Single-Center, Retrospective Analysis","volume":"262","author":"Tochigi","year":"2024","journal-title":"Tohoku J. Exp. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2023.09.010","article-title":"Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer","volume":"178","author":"Zammarrelli","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.22.02152","article-title":"Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309\/KEYNOTE-775","volume":"41","author":"Makker","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000011965","article-title":"Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: A Hellenic cooperative oncology group study","volume":"56","author":"Bafaloukos","year":"1999","journal-title":"Oncology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e000926","DOI":"10.1136\/esmoopen-2020-000926","article-title":"Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers","volume":"5","author":"Zanfagnin","year":"2020","journal-title":"ESMO Open"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ygyno.2010.10.015","article-title":"Phase II study of fulvestrant in recurrent\/metastatic endometrial carcinoma: A Gynecologic Oncology Group study","volume":"120","author":"Covens","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1385\/MO:23:4:543","article-title":"Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma","volume":"23","author":"Karagol","year":"2006","journal-title":"Med. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/IGC.0000000000000862","article-title":"A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer","volume":"27","author":"Pautier","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1006\/gyno.2000.5865","article-title":"A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study","volume":"78","author":"Rose","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ygyno.2013.02.039","article-title":"Phase II study of fulvestrant 250 mg\/month in patients with recurrent or metastatic endometrial cancer: A study of the Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie","volume":"129","author":"Emons","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/IGC.0000000000000044","article-title":"Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: A multicenter phase 2 trial (AGO-GYN5)","volume":"24","author":"Emons","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Lindemann, K., Malander, S., Christensen, R.D., Mirza, M.R., Kristensen, G.B., Aavall-Lundqvist, E., Vergote, I., Rosenberg, P., Boman, K., and Nordstr\u00f8m, B. (2014). Examestane in advanced or recurrent endometrial carcinoma: A prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO). BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-68"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ygyno.2003.09.018","article-title":"Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group study","volume":"92","author":"Whitney","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/JCO.2001.19.2.364","article-title":"Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study","volume":"19","author":"Thigpen","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.1999.17.6.1736","article-title":"Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: A dose-response study by the Gynecologic Oncology Group","volume":"17","author":"Thigpen","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00006250-198602000-00019","article-title":"Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma","volume":"67","author":"Piver","year":"1986","journal-title":"Obstet. Gynecol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1006\/gyno.1996.4544","article-title":"A phase II study of leuprolide in advanced\/recurrent endometrial cancer","volume":"64","author":"Covens","year":"1997","journal-title":"Gynecol. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0090-8258(88)80012-X","article-title":"Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status","volume":"31","author":"Ayoub","year":"1988","journal-title":"Gynecol. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00000421-200102000-00007","article-title":"Megestrol and tamoxifen in patients with advanced endometrial cancer: An Eastern Cooperative Oncology Group Study (E4882)","volume":"24","author":"Pandya","year":"2001","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.1996.14.2.357","article-title":"High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study","volume":"14","author":"Lentz","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1006\/gyno.1999.5538","article-title":"A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: A French anticancer federation study","volume":"75","author":"Vennin","year":"1999","journal-title":"Gynecol. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0028-2243(84)90071-6","article-title":"Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma","volume":"17","author":"Rendina","year":"1984","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"16173","DOI":"10.1002\/cam4.6276","article-title":"Should we abandon hormonal therapy in endometrial cancer? Outcomes of recurrent and metastatic endometrial cancer treated with systemic progestins","volume":"12","author":"Kulkarni","year":"2023","journal-title":"Cancer Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2003.11.008","article-title":"Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group study","volume":"92","author":"Fiorica","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0090-8258(89)90016-4","article-title":"Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate","volume":"35","author":"Hoffman","year":"1989","journal-title":"Gynecol. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ygyno.2019.05.007","article-title":"Phase 2 study of anastrozole in recurrent estrogen (ER)\/progesterone (PR) positive endometrial cancer: The PARAGON trial\u2014ANZGOG 0903","volume":"154","author":"Mileshkin","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0090-8258(03)00149-5","article-title":"Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: A Gynecologic Oncology Group study","volume":"89","author":"Covens","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00000421-200212000-00004","article-title":"Goserelin acetate as treatment for recurrent endometrial carcinoma: A Gynecologic Oncology Group study","volume":"25","author":"Asbury","year":"2002","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1002\/cncr.24197","article-title":"Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma","volume":"115","author":"Ramondetta","year":"2009","journal-title":"Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.22.00628","article-title":"A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer","volume":"41","author":"Konstantinopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ygyno.2015.12.025","article-title":"Temsirolimus in women with platinum-refractory\/resistant ovarian cancer or advanced\/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)","volume":"140","author":"Emons","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/bjc.2013.183","article-title":"Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO","volume":"108","author":"Favier","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1002\/cncr.30286","article-title":"A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)","volume":"122","author":"Makker","year":"2016","journal-title":"Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ygyno.2014.12.019","article-title":"Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma","volume":"136","author":"Matulonis","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ygyno.2014.01.015","article-title":"Temsirolimus with or Without megestrol acetate and tamoxifen for endometrial cancer: A gynecologic oncology group study","volume":"132","author":"Fleming","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/bjc.2016.430","article-title":"Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: A stratified type I-type II study from the GINECO group","volume":"116","author":"Heudel","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/1078-0432.CCR-19-0471","article-title":"Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study","volume":"26","author":"Soliman","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamaoncol.2022.1047","article-title":"Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined with Anastrozole in Patients with Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1\/2 Randomized Clinical Trial","volume":"8","author":"Heudel","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1200\/JCO.2010.34.1578","article-title":"Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: A trial of the NCIC Clinical Trials Group","volume":"29","author":"Oza","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.2014.58.8871","article-title":"Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma","volume":"33","author":"Oza","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ygyno.2016.04.019","article-title":"A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer","volume":"142","author":"Birrer","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2021.12.031","article-title":"A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study","volume":"164","author":"Slomovitz","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ijc.32783","article-title":"Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer","volume":"147","author":"Myers","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ygyno.2019.09.024","article-title":"Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology\/GOG study","volume":"155","author":"Westin","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/cncr.32677","article-title":"Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway","volume":"126","author":"Rubinstein","year":"2020","journal-title":"Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ygyno.2023.09.013","article-title":"A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer","volume":"178","author":"Han","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"100532","DOI":"10.1016\/j.gore.2019.100532","article-title":"Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)","volume":"31","author":"Santin","year":"2020","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1470-2045(23)00016-5","article-title":"Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): A multicentre, open-label, randomised, controlled, phase 2 trial","volume":"24","author":"Pignata","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab Plus Carboplatin\/Paclitaxel Followed by Maintenance Durvalumab with or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(24)00334-6","article-title":"Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Colombo","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2009.09.025","article-title":"Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study","volume":"116","author":"Fleming","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e2200609","DOI":"10.1200\/PO.22.00609","article-title":"Pertuzumab Plus Trastuzumab in Patients with Endometrial Cancer with ERBB2\/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study","volume":"7","author":"Ahn","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ygyno.2023.03.013","article-title":"DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma","volume":"172","author":"Arend","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ygyno.2015.07.018","article-title":"A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology\/Gynecologic Oncology Group study","volume":"138","author":"Bender","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ygyno.2012.08.020","article-title":"A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study","volume":"127","author":"Coleman","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ygyno.2014.10.001","article-title":"A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology\/Gynecologic Oncology Group Study","volume":"135","author":"Dizon","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygyno.2014.05.016","article-title":"A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia","volume":"134","author":"Castonguay","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1158\/1078-0432.CCR-19-2576","article-title":"Phase II Trial of Cabozantinib in Recurrent\/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322\/PHL86)","volume":"26","author":"Dhani","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2014.07.083","article-title":"A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology\/Gynecologic Oncology Group Study","volume":"135","author":"Powell","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ygyno.2007.01.019","article-title":"A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study","volume":"105","author":"McMeekin","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"106","DOI":"10.21037\/atm-22-6463","article-title":"Efficacy and safety of apatinib in patients with recurrent uterine malignancy: A prospective, single-center, single-arm, phase 2 study","volume":"11","author":"Ren","year":"2023","journal-title":"Ann. Transl. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ygyno.2015.07.006","article-title":"A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1\/2 neutralizing peptibody, in patients with persistent\/recurrent carcinoma of the endometrium: An NRG\/Gynecologic Oncology Group trial","volume":"138","author":"Moore","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(15)70159-2","article-title":"Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: A non-randomised, open-label, two-group, two-stage, phase 2 study","volume":"16","author":"Konecny","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/ijgc-2023-004781","article-title":"PAZEC: A Dutch Gynaecological Oncology Group open-label, multicenter, phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer","volume":"34","author":"Westermann","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ygyno.2021.06.032","article-title":"Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer","volume":"162","author":"Backes","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ygyno.2012.07.127","article-title":"Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer","volume":"127","author":"Leslie","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ygyno.2013.02.019","article-title":"A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study","volume":"129","author":"Leslie","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ygyno.2015.04.005","article-title":"A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1\/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology\/Gynecologic Oncology Group study","volume":"138","author":"Coleman","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1200\/JCO.2008.20.6995","article-title":"Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic oncology group trial 129-P","volume":"27","author":"Dizon","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2015.04.026","article-title":"Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer","volume":"138","author":"McMeekin","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1200\/JCO.20.03167","article-title":"Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma","volume":"39","author":"Liu","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/oncolo\/oyad164","article-title":"A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent\/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma","volume":"28","author":"Atkins","year":"2023","journal-title":"Oncologist"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.35151","article-title":"NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib\/olaparib in women with recurrent, persistent, or metastatic endometrial cancer","volume":"130","author":"Rimel","year":"2024","journal-title":"Cancer"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ygyno.2024.05.025","article-title":"Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study","volume":"186","author":"Berton","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1006\/gyno.1996.0074","article-title":"Chemotherapy plus sequential hormonal therapy for advanced and recurrent endometrial carcinoma: A phase II study","volume":"60","author":"Pinelli","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0002-9378(81)90280-5","article-title":"Chemotherapy of advanced and recurrent endometrial carcinoma with cyclophosphamide, doxorubicin, 5-fluorouracil, and megestrol acetate","volume":"140","author":"Deppe","year":"1981","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1006\/gyno.1996.0276","article-title":"Long-term follow-up of gonadotrophin-releasing hormone analog treatment for recurrent endometrial cancer","volume":"63","author":"Jeyarajah","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0090-8258(89)90839-1","article-title":"Tamoxifen therapy in advanced\/recurrent endometrial carcinoma","volume":"32","author":"Quinn","year":"1989","journal-title":"Gynecol. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"181","DOI":"10.6004\/jnccn.2023.0006","article-title":"Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Yashar","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejogrb.2021.11.423","article-title":"British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: Recommendations for practice","volume":"270","author":"Morrison","year":"2022","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1200\/JCO.23.01279","article-title":"Radiation Therapy with or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology\/GOG Prospective Randomized Multicenter Clinical Trial","volume":"42","author":"Klopp","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(25)00379-1","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial","volume":"26","author":"Post","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.24.01121","article-title":"Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma","volume":"43","author":"Matei","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ijrobp.2020.09.016","article-title":"Current Status of Clinical Trials for Cervical and Uterine Cancer Using Immunotherapy Combined with Radiation","volume":"109","author":"Dyer","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: From the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41591-021-01458-8","article-title":"Accelerating the translational medicine cycle: The Academia Europaea pilot","volume":"27","author":"Hegyi","year":"2021","journal-title":"Nat. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2091\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:46:46Z","timestamp":1782967606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":158,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18132091"],"URL":"https:\/\/doi.org\/10.3390\/cancers18132091","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]}}}